BRL49653C In Type 2 Diabetes -Comparison Study With Pioglitazone And Placebo By Monotherapy-

• Status: Completed
• Trial end date: 2007-05-31
• Target enrollment: 0
• Participant gender: All

Summary

This study is designed to compare the efficacy and safety of BRL49653C versus pioglitazone and placebo.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: GlaxoSmithKline
• Treatments: Pioglitazone; Rosiglitazone

Criteria

Inclusion criteria:

• Type 2 diabetes mellitus.

• Managed by diet therapy.

• Must have adequate blood, liver and kidney function.

Exclusion criteria:

• Serious cardiovascular disease or serious hepatic disease.